Accendra Health Q2 2026 adjusted EBITDA drops to $60 million; GAAP continuing-ops net loss widens to $89 million - ACH News | RalliesAccendra Health Q2 2026 adjusted EBITDA drops to $60 million; GAAP continuing-ops net loss widens to $89 million
A
ACH• Q2 2026 results
- Accendra Health posted a GAAP loss from continuing operations of $89 million in Q2 2026, versus a $84 million loss a year earlier.
- Adjusted EBITDA (non-GAAP) fell to $60 million from $97 million in Q2 2025.
- Free cash flow (non-GAAP) swung to a $25 million outflow from a $15 million inflow in the prior-year quarter.
- Balance sheet optimization cut total funded debt to $1.75 billion at June 30, 2026 from $2.12 billion at March 31, 2026.
2026 outlook
- Revenue of $2.45 billion to $2.55 billion.
- Adjusted EBITDA (non-GAAP) of $300 million to $320 million.
- Free cash flow expected to be near breakeven to slightly positive.
